Tekcapital plc Technology Acquisition (2331J)
April 02 2015 - 2:00AM
UK Regulatory
TIDMTEK
RNS Number : 2331J
Tekcapital plc
02 April 2015
2 April 2015
Tekcapital Plc
("Tekcapital", "the Company" or "the Group")
Technology Acquisition
Tekcapital acquires exclusive patent licence to a new technology
for the non-invasive measurement of glucose in saliva
Tekcapital plc (AIM: TEK), an international provider of
technology and intellectual property services, is pleased to
announce that it has acquired the exclusive license to a patent for
the measurement of glucose in saliva from Arizona State University.
The patent, # 8815178 B2, addresses the need for a safe, fast and
non-invasive method and device to collect and sample glucose in
saliva. The device allows trace fluid samples from a biological
surface to be obtained for electrochemical analysis and the
subsequent detection of analytes. The device can be used to collect
fluid from the mouth and for such samples to be subsequently
processed to detect glucose, a metabolic product in saliva, using
disposable biosensor strips.
The Directors believe this technology represents an important
potential improvement for the repeated measurement of glucose in
Type II diabetics, without requiring a blood sample from a finger
prick, which is the current FDA standard glucometer method of
measurement.
Market potential
According to the World Health Organization, about 347 million
people worldwide have diabetes ( 9% of the world's population).
There is an emerging global epidemic of diabetes that can be traced
back to rapid increases in overweight, including obesity and
physical inactivity. Diabetes is a chronic disease that occurs
either when the pancreas does not produce enough insulin, a hormone
that regulates blood sugar, or when the body cannot effectively use
the insulin it produces. Hyperglycaemia, or raised blood sugar, is
a common effect of uncontrolled diabetes and over time leads to
serious damage to many of the body's systems, especially the nerves
and blood vessels.
The current standard for self-glucose monitoring technologies,
used throughout the world to measure blood glucose in diabetics, is
pricking the finger to draw a blood sample and placing the blood on
a strip for insertion into a glucometer. There is a general dislike
of the pain and inconvenience caused by this method, leading to
fewer tests being performed, which may result in inadequate blood
glucose control and complications from the disease. Furthermore,
the testing itself can also cause fainting and blood-borne
infection.
The Directors believe that a non-invasive, strip-based
technology to measure glucose in saliva could be transformative to
both patients and the glucose monitoring industry and if
successful, may become one of the monitoring techniques of
choice.
Commenting on the announcement, Dr. Clifford M. Gross, Executive
Chairman of Tekcapital plc, said:
"We are excited to have acquired the exclusive license to this
important patent from Arizona State University for the measurement
of glucose in saliva. The self-monitoring of blood glucose is a
significant industry and we look forward to commercializing this
technology with one or more leading medical device companies that
can benefit by making it easier and painless for diabetics to
measure glucose."
Dr. Yash Vaishnav, Vice President of Business Development at
Arizona Technology Enterprises said:
"We are pleased to have exclusively licensed this new technology
for the non-invasive, saliva-based measurement of glucose to
Tekcapital and we are excited about the potential for this
promising technology to improve the quality of life for diabetics
and become a method of choice for routine monitoring of glucose
levels."
For further information please contact:
+1 305 200 3450
Tekcapital Plc Ext 305
Clifford M. Gross cgross@tekcapital.com
Arizona Technology Enterprises +1 202-903-6247
Derek Sarley sarley@pinkstongroup.com
Northland Capital Partners +44 (0) 20 7382
Limited (NOMAD & Broker) 1100
William Vandyk (Corporate
Finance) wvandyk@northlandcp.co.uk
John Howes (Corporate Broking)
Optiva Securities Limited +44 (0) 20 3137
(Co-Broker) 1904
Jeremy King / Vishal Balasingham jeremy.king@optivasecurities.com
+44 (0) 20 3727
FTI Consulting, LLP 1000
Chris Lane / Emma Appleton
/ Roger Newby tekcapital@fticonsulting.com
Tekcapital plc - The World's Largest University Network for Open
Innovation
Tekcapital helps clients profit from new, university-developed
intellectual properties. With our proprietary discovery search
engine, linked to 4,000+ universities in 160 countries, coupled
with expert scientific review, we provide a turn-key service to
make it easy for clients to find and acquire the IP they need to
create a competitive advantage. Tekcapital plc is listed on the AIM
market of the London Stock Exchange (AIM: symbol TEK) and is
headquartered in Oxford, in the UK. For more information, please
visit www.tekcapital.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQBUGDSUXGBGUB
Tekcapital (LSE:TEK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tekcapital (LSE:TEK)
Historical Stock Chart
From Apr 2023 to Apr 2024